Compare BioNano Genomics Inc (BNGO) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs MPLX LP — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while MPLX LP trades at $56.54 (market cap $57.34B). The key difference: MPLX LP is far larger — about 4343.9× BioNano Genomics Inc's market cap, and MPLX LP pays a 7.62% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MPLX | |
|---|---|---|
Market Cap | $13.20M | $57.34B |
Sector | Health | Technology |
52-Week High | $4.92 | $59.17 |
52-Week Low | $1.09 | $47.80 |
Enterprise Value | $15.81M | $81.97B |
Dividend Yield | — | 7.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
MPLX trades at $57.21, up 0.46% today, with a bullish technical outlook supported by moving averages and a consensus price target of $60.60. The company reported strong profitability with a 41.24% net income margin and robust cash flow from operations of $5.91B in 2025. Recent earnings showed beats in Q3 and Q4 2025 but a miss in Q1 2026, with Q2 2026 results pending. A dividend of $1.08 was declared for H1-26, reinforcing income appeal.
The stock presents a compelling value with a P/E of 12.23 and high analyst buy consensus (71.43%), though risks include earnings volatility and high debt-to-asset ratio of 90.06%. Upside is supported by stable midstream operations and Permian Basin exposure, but investors should monitor Q2 2026 earnings for growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
